Session » Miscellaneous Rheumatic & Inflammatory Diseases Poster III: Therapies
-
Abstract Number: 1626
Long-Term Follow-Up of Renal Transplantation Due to Lupus Nephritis. Single Universitary Center Experience
-
Abstract Number: 1627
Phase I Trial of High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients with Mild COVID-19: A Study in the Effects of Shifting Public Opinion on Patient Enrollment
-
Abstract Number: 1628
Management of Gout After Pegloticase; Observations of US Clinical Practice from Trio Health and the American Rheumatology Network (ARN)
-
Abstract Number: 1629
Management of Gout with Pegloticase; Real-World Utilization and Outcomes from Trio Health and the American Rheumatology Network (ARN)
-
Abstract Number: 1630
Long-term Safety of Tildrakizumab in Patients with Moderate to Severe Plaque Psoriasis: Incidence of Confirmed Major Adverse Cardiovascular Events Through 3 Years (148 Weeks) from Two Phase 3 Trials
-
Abstract Number: 1631
No Increased Risk of Liver Dysfunction from Tildrakizumab Treatment: Post Hoc Analyses of the Tildrakizumab Psoriasis Clinical Program
-
Abstract Number: 1632
Long-Term Efficacy and Safety of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes – First Interim Analysis of the FMF-TRAPS-HIDS/MKD Subgroup of the RELIANCE Registry
-
Abstract Number: 1633
A Randomized, Double-Blind, Placebo-Controlled Study of Anakinra in Pediatric and Adult Patients with Still’s Disease
-
Abstract Number: 1634
Etiologies and Management of Hemophagocytic Lymphohistiocytosis: Is It Time for an Updated Protocol and Targeted Treatments?
-
Abstract Number: 1635
Profile of Topical Diclofenac Sodium Gel 1% (Voltaren®) Users in a United States Longitudinal Electronic Health Records Database